Celularity unveils size of series A

Celularity Inc. (Warren, N.J.) revealed on Thursday that it has raised more than $250 million in series A funding and assets from Celgene Corp. (NASDAQ:CELG), three other biotechs and private investors. The cell therapy, regenerative medicine and biosourcing company is using placenta-derived cells to treat diseases ranging from Crohn's disease to cancer (see BioCentury Innovations, Feb. 15).

In September, the company said it raised an undisclosed amount in a series A round from Celgene, Sorrento Therapeutics Inc. (NASDAQ:SRNE), United Therapeutics Corp. (NASDAQ:UTHR), Human Longevity Inc. (San Diego, Calif.) and undisclosed private investors. The four biotechs collectively own about 50% of Celularity. At the time, Celularity said it had a portfolio of immuno-oncology and regenerative therapies (see BioCentury Extra, Aug. 21, 2017)...